![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Department of Biochemistry,1 Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology & Nutrition,2 Cell and Developmental Biology,3 Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232,4 Department of Biochemistry and Molecular Biology F7-26, Louisiana State University Health Sciences Center and Feist-Weiller Cancer Center, 1501 Kings Highway, Shreveport, Louisiana 71130,5 Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232,6 Department of Pathology, University of California, Irvine, D440 Medical Sciences I, Irvine, California 92697-4800,7 Department of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232,8 Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232,9 Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232,10 Department of Veterans Affairs Medical Center, Nashville, Tennessee 37232,11
Received 17 March 2005/ Returned for modification 5 May 2005/ Accepted 7 August 2005
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
MTG family members display approximately 85% sequence similarity (3) and contain four conserved subdomains with up to 95% identity (5, 8). Based on homology to MTG8, it was anticipated that MTG16 and MTGR1 also act as transcriptional corepressors. MTG16 is 92% homologous to MTG8, and the murine form of MTG16, Eto2, interacts with multiple HDACs and N-CoR (1). In contrast to MTG8, Eto2 failed to interact with mSin3A (1). The MTG family members also heterodimerize, and this property allowed the identification of MTGR1 as a RUNX1-MTG8-associated protein (18). Although it associates with MTG8 and the t(8;21) fusion protein, the molecular function of MTGR1 is unknown.
While two of the three MTG family members are disrupted by chromosomal translocations, the MTG family members are widely expressed, suggesting that this gene family functions in multiple tissues. Indeed, targeted disruption of Mtg8 (CBFA2T1) revealed that it plays a critical role in gut development as 25% of the Mtg8-deficient mice showed a deletion of the midgut, fusing the proximal small intestine to the distal colon (4). The mice that retained the midgut were 30 to 50% smaller than controls and showed reduced viability, with approximately 80% dying by 15 days of age. The failure to thrive was presumed to be due to thinning of the intestinal wall, with fewer, blunted, and disorganized villi leading to poor absorption of nutrients. However, all four epithelial cell types were present in the gut and the ratios of each cell type were not significantly different from those of wild-type littermates (4).
Based on its homology to MTG8 and MTG16, we investigated the role of Mtgr1 in transcriptional control. When tethered to a promoter, Mtgr1 is a strong transcriptional repressor that recruits corepressors and HDAC3. To gain insight into the physiological role of Mtgr1, we generated mice with a targeted disruption of Mtgr1 (also known as CBFA2T2). Although the mice are grossly normal, by 6 weeks of age there is a dramatic decrease in the number of cells comprising the secretory lineage of the small intestine, including goblet, Paneth, and enteroendocrine cells. Thus, this transcriptional corepressor is required for the maintenance of the secretory cell lineage in the small intestine.
|
MATERIALS AND METHODS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
A murine Mtgr1 cDNA was obtained as an IMAGE clone and sequenced (accession number pending). The cDNA representing the short form of the molecule, Mtgr1a (28), was isolated from the IMAGE clone and the 5' end engineered to contain XbaI and MluI restriction sites. This cDNA was subcloned into the XbaI and SalI sites of the pBluescript KS vector. The cDNA was released with MluI and SalI and subcloned into the pCMV5 M2 vector, described previously (9), to create Gal-Mtgr1a. In the cloning of this cDNA, we noted that alternative splicing creates two forms of Mtgr1a, with one containing a single glutamic acid at codon 413, which we designated Mtgr1a, and the other form containing two glutamic acids at codons 413 and 414, which we call Mtgr1a(+E). While we used Mtgr1a for all of our experiments, the Mtgr1(+E) form of the protein gave the same results in transcription assays; thus, the two forms of the protein appear to be functionally equivalent. The Gal-MTG8 expression plasmid was constructed previously (1).
Several plasmids used in our assays were kindly provided by the following investigators. FLAG-tagged HDAC1 to -6 constructs were provided by E. Seto (Moffitt Cancer Center, Tampa, FL). Myc-HDAC8 was provided by E. Hu (SmithKline Beecham Pharmaceuticals). Hemagglutinin-HDAC7 and full-length N-CoR tagged with the FLAG epitope were kindly provided by R. Evans (17). The mSin3A cDNA was provided by D. Ayer (University of Utah) in the pVZ vector. The FLAG epitope tag was added to mSin3A by engineering a KpnI site at the 5' end and subcloning the mSin3A cDNA into the pFLAG-CMV-2 expression vector (Sigma).
The pPNT vector used for making the targeting construct was provided by the Vanderbilt-Ingram Cancer Center Transgenic Mouse/Embryonic Stem Cell Shared Resource as previously described (32). The construct used for targeting the Mtgr1/CBFA2T2 locus was made by restriction mapping a BAC clone isolated from an AB1 library. An 11-kb XbaI fragment was identified that contained the region to be disrupted. From this 11-kb XbaI fragment, a 6.5-kb StuI-SmaI fragment was subcloned into a blunt-ended, XbaI-cut pPNT vector. A construct containing the StuI-SmaI fragment in the correct orientation was isolated, digested with XhoI, and filled in with the Klenow fragment of DNA polymerase. A 1.7-kb SmaI-XbaI fragment was filled in with Klenow and subcloned into the filled-in XhoI site. The resulting construct was linearized with NdeI and electroporated into TL1 embryonic stem (ES) cells. DNA isolated from the resulting single-cell clones was digested with EcoRI and analyzed by Southern blotting for homologous recombination. Of the multiple clones shown to have a targeted disruption of the CBFA2T2 locus, three were chosen for injection into C57BL/6 blastocysts. Male chimeric mice were mated with C57BL/6 females, and agouti pups were tested for disruption of the CBFA2T2 locus. All three ES cell clones produced chimeras capable of transmitting mutated CBFA2T2 to their progeny. Two of these lines, A7 and 6A6, were continued for further analysis.
In addition, the 5' end of Mtgr1 was amplified by PCR to generate a 380-bp fragment and subcloned into BamHI/XhoI-digested pGEX4T-1 (Amersham-Pharmacia) to generate Mtgr1 recombinant protein for making antiserum. The oligonucleotides used to generate the PCR product were Mtgr1-138T (5'-GCGGATCCGAGAAAAGGGTGCCAGCAATG-3') and Mtgr1-518B (5'-GCCTCGAGTTAAGTAGCCGGCAGCTGTTGATT-3').
Cell culture. Cos-7 and K562 cells were maintained in Dulbecco modified Eagle medium (DMEM; BioWhittaker Inc., Walkersville, MD) or RPMI medium, respectively, containing 10% fetal calf serum (Sigma or Atlanta Biologicals), 50 U/ml penicillin, 50 µg/ml streptomycin, and 2 mM L-glutamine (all from BioWhittaker). NIH 3T3 cells were maintained in DMEM containing 10% calf serum (HyClone), 50 U/ml penicillin, 50 µg/ml streptomycin, and 2 mM L-glutamine (all from BioWhittaker). ES cells were grown on irradiated mouse embryo fibroblast (MEF) feeder layers in DMEM containing 15% fetal calf serum, 0.1 mM nonessential amino acids, 2 mM L-glutamine, 50 µg/ml gentamicin, 103 U/ml leukemia inhibitory factor, and 55 µM ß-mercaptoethanol (all from Gibco/Invitrogen). MEFs were generated from single embryos by standard procedures. They were maintained in DMEM containing10% calf serum (HyClone), 50 U/ml penicillin, 50 µg/ml streptomycin, and 2 mM L-glutamine (all from BioWhittaker) by using a standard 3T3 protocol. Some were grown in DMEM containing 10% fetal calf serum, 0.1 mM nonessential amino acids, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine (BioWhittaker), and 55 µM ß-mercaptoethanol (Sigma) by using a 3T9 protocol.
Coimmunoprecipitations and immunoblotting. Cos-7 cells (3 x 106 cells in 100-mm-diameter dishes) were transfected with Lipofectamine reagent (Invitrogen) according to the manufacturer's instructions. Typically, 1.5 to 3.5 µg of each of the expression plasmids was cotransfected. When necessary, vector DNA (pCMV5 or pCMV5 M2) was added to normalize the amount of DNA (5 µg total). Approximately 48 to 52 h posttransfection, cells were harvested and extracted with lysis buffer (phosphate-buffered saline supplemented with 1 µg/ml leupeptin, 0.2 mM phenylmethylsulfonyl fluoride, and 0.1 trypsin inhibitor U/ml aprotinin and containing 0.5% Triton X-100, 0.1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate). A portion of the cell lysate was removed for immunoblot analysis and the remainder incubated for 1 h with affinity-purified primary antibody (anti-Mtgr1, anti-Myc 9E10 [Covance], and anti-HA [Covance]). A 20-µl aliquot of a 50% slurry of protein A (Amersham-Pharmacia)- or protein G-Sepharose (Sigma) was then added, the mixture was incubated for 30 min to collect the immune complexes, and these complexes were washed three times at 4°C with lysis buffer. For FLAG or GAL4 coimmunoprecipitations, 20 µl of a 50% slurry of anti-FLAG M2 beads (Sigma) or anti-GAL4 beads (Santa Cruz Biotechnology), respectively, was added to the lysates and the mixture was incubated for 90 min at 4°C and washed three times at 4°C with lysis buffer. For the endogenous association, lysates from K562 cells were immunoprecipitated with anti-mSin3A (K-20; Santa Cruz) or nonspecific rabbit immunoglobulin G and collected with protein A-Sepharose as described above. Immunoblot analysis was performed with the antibodies indicated in the figures as previously described (1).
In situ hybridization. Two probes for in situ analysis were generated by PCR with the oligonucleotides MTGR1-776T (5'-GAATTCCAGTCCGGAAAGGAGGGACGA-3') and MTGR1-1094B (5'-GAATTCCCTTTCTGTCAAACGGTGGTC-3') as one primer set and MTGR1-1699T (5'-GAGTCTACATGGCCACAGTCC-3') and MTGR1-2020B (5'-GAAGCTGTGGAGTGCCTCTTG-3') as a second primer set. Both PCR products were subcloned into pBluescript KS II. RNA probes, labeled with digoxigenin (DIG), were made from linearized plasmid and T7 polymerase for antisense probes or T3 polymerase for sense probes by using DIG RNA labeling mix (Roche, Indianapolis, IN). In situ hybridization was performed on frozen sections of paraformaldehyde-fixed small intestine isolated from mice perfused with 4% paraformaldehyde and placed into 4% paraformaldehyde at 4°C for overnight fixation. Rolls of the duodenum, jejunum, and ileum were quick-frozen with Super Friendly Freeze-it (Fisher) and 10-µm sections placed on glass slides. Sections were desiccated at room temperature and fixed in methanol at –20°C for 2 h. After inactivating endogenous peroxidases with 1% peroxide, sections were prehybridized at 60°C for 1 h, followed by hybridization with either antisense or sense probes for 18 h at 60°C. Slides were then washed with 0.2x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% Tween 20 at 60°C for 1 h. Sections were then blocked with 5% goat serum and 2% hybridization blocking reagent (Roche) for subsequent incubation with an anti-DIG antibody conjugated with horseradish peroxidase overnight (Roche). After washing the sections with phosphate-buffered saline-0.1% Tween 20, the locations of the probes were visualized with a TSA kit (Perkin-Elmer, Boston, MA) in accordance with the manufacturer's protocol. TSA cy3 was used with the TSA kit and probes visualized with a Zeiss Axiophot II with a cy3 fluorescence filter set. Pictures were taken with a spot camera with equal exposure times for antisense and sense probes.
Immunohistochemistry and histology. Tissue was fixed in buffered formalin overnight at room temperature prior to embedding in paraffin and sectioning. Antibodies used for immunohistochemistry included anticryptdin antiserum (30), anti-chromogranin A (ImmunoStar, Hudson, WI), anti-Gfi1 (a kind gift from H. Bellen, Baylor College of Medicine), and antivillin (Chemicon). Antigen retrieval was performed on all of the sections with a neutral-pH antigen retrieval agent (DakoCytomation, Carpinteria, CA). The rabbit Envision+HRP System (DakoCytomation) and diaminobenzidine or NovaRed (Vector Laboratories, Burlingame, CA) was used to produce visible results. Sections were lightly counterstained with Mayer's hematoxylin prior to mounting. Hematoxylin-and-eosin (H&E) and periodic acid-Schiff (PAS) staining was performed according to standard procedures.
Northern blot analysis. Tissue isolated from mice was frozen in liquid nitrogen and stored at –80°C. Frozen tissue was pulverized with a mortar and pestle and total RNA isolated with Trizol reagent (Invitrogen). Total RNA (15 µg) was analyzed by RNA blot analysis as previously described (21), with Hybond-N+ membrane (Amersham-Pharmacia). The Math1 and Hes1 cDNA probes were made by reverse transcription-PCR from total RNA isolated from mouse small intestine and subcloned into pBluescript KS II (Stratagene). The probe for Mtgr1 was a mouse EcoRI fragment spanning codons 129 through 395.
Bone marrow transplantation. Bone marrow was harvested from 6- to 8-week-old Mtgr1-null donor mice injected 4 days before with 140 mg 5'-fluorouracil (Acros) per kg of weight. Approximately 5 x 105 to 1 x 106 cells were injected via the tail vein into lethally irradiated 6- to 8-week-old syngeneic recipient mice. Irradiation was 9 rads in a single dose, which caused death in nontransplanted control mice within 10 to 12 days. Six weeks posttransplantation, the small intestine was harvested, fixed, and sectioned prior to staining with H&E.
|
RESULTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Creation of Mtgr1-null mice. Defining a biological function for a transcriptional corepressor or placing a corepressor into a signaling pathway is a difficult task because these proteins act as cofactors or scaffolds without enzymatic activity or DNA binding capacities. Therefore, we took a genetic approach to attempt to define the biological functions that require Mtgr1. To inactivate Mtgr1 (CBFA2T2 is the designation of the Mtgr1 locus), we inserted the G418 resistance gene (Neo) into exon 7, which is within the first conserved domain that is found in all family members and the Drosophila homologue Nervy (Fig. 2A). Exon 7 was selected because of the extensive alternative splicing at the 5' end of the gene (upstream of exon 4) (28). In addition, if exon 7 is spliced out because of the presence of Neo, a stop codon would be introduced into the mRNA when exon 6 is spliced to exon 8. We were able to identify multiple ES cell single-cell clones with Neo inserted correctly. Three clones were chosen for blastocyst injection, and the mutation was transmitted to progeny from all three ES cell lines. Examination of progeny by Southern blotting indicated the presence of Neo in one allele of the heterozygous animals and both alleles of the null animals (Fig. 2B, left). Two of these lines were analyzed in detail.
|
Mtgr1-null mice are small. On a mixed SvEv129 x C57BL/6 genetic background, mice lacking Mtgr1 were obtained at the expected frequency, were fertile, and appeared anatomically normal. Although there is considerable diversity in the size of inbred mouse strains (e.g., mice can vary by 3 to 4 g within a litter), careful inspection indicated that the Mtgr1-null mice were 15 to 20% smaller than littermate controls (Fig. 3A). While this could be due to a feeding disorder or to a gut phenotype, as observed with Eto/Mtg8-null mice (4), the Mtgr1-null mice are shorter (Fig. 3A), suggesting that there is a developmental defect rather than a nutrient deficiency. Next, mice lacking Mtgr1 were backcrossed into a C57BL/6J background to create a more homogeneous genetic background to analyze Mtgr1 deficiency. After five backcrosses, the ratios of heterozygous to homozygous mice became skewed from the expected Mendelian ratios, with only 12% of the animals being homozygous null rather than the expected 25%. The size difference also increased, with null animals averaging nearly 30% less than their wild-type littermates (Fig. 3B). Examination of serum levels of growth hormone and insulin-like growth factor showed no significant differences between wild-type and null animals (data not shown). In addition, when embryos were harvested at 18.5 days postcoitus, the expected Mendelian ratios were present and the weights of Mtgr1-null animals averaged 20 to 30% less than those of the wild-type embryos (Fig. 3C). This indicates that roughly half of the Mtgr1-deficient animals were dying sometime between 18.5 days postcoitus and 21 days postbirth. In addition, the difference in the sizes of the animals is a developmental defect and not due to poor nutrient absorption, as their weight is affected prior to birth. Furthermore, MEFs lacking Mtgr1 grew at the same rate as wild-type cells in vitro and no differences in intrinsic cell size were observed (data not shown).
|
|
|
|
Because inflammation can be associated with erosion of the intestinal epithelium, we tested the possibility that the reduction of the secretory cells in the Mtgr1-null mice was due to an inflammatory process, rather than an intrinsic defect in the epithelium. Bone marrow lacking Mtgr1 was transplanted into wild-type mice that were lethally irradiated to create mice lacking Mtgr1 only within the hematopoietic system. The intestinal epithelium was analyzed after 6 weeks to allow the epithelium time to recover from the irradiation and to allow time for any reduction in the levels of the secretory cells, if any, as the reduction of these cells began at 4 week of age (Fig. 4). By comparison to adult Mtgr1-null small intestines, the intestinal epithelium from wild-type mice transplanted with Mtgr1-null marrow contained normal numbers of goblet cells (Fig. 6), suggesting that the phenotype observed was due to an intrinsic defect in the epithelium.
|
|
Mtgr1-null mice retain Gfi1-positive progenitor cells. In the small intestine, Hes1 is required for the development of the enterocyte lineage (16), Math1 is required for the secretory lineage (35), and Tcf4 is required for stem cell self-renewal (2, 19) (summarized in Fig. 8A). Given the key roles of these factors in gut development, we examined their expression in the small intestines of 8-week-old Mtgr1-deficient mice (Fig. 8B). The levels of Tcf4 were unchanged, but Hes1 was up regulated approximately twofold and Math1 was down regulated approximately fourfold (Fig. 8B). The changes in Hes1 and Math1 expression may contribute to the loss of the secretory lineage in the small intestines of Mtgr1-null mice.
Given that Math1 is expressed in secretory cells and that it is required for the formation of the secretory lineage (35), we used immunohistochemistry to examine whether secretory lineage progenitor cells were retained in the absence of Mtgr1 to determine at what level the defect in secretory lineage maturation occurred. We used two different antibodies directed to Math1, but neither worked in small intestinal sections (data not shown). Therefore, because Gfi1 is downstream of Math1 in small intestinal development (Fig. 8A and reference 31) and Gfi1 is required for the formation of goblet and Paneth cells (31), we used anti-Gfi1 in immunohistochemistry (Fig. 8C). Compared to wild-type control littermates, the Mtgr1-null mice appeared to have similar numbers of Gfi1-positive cells in the crypts of the small intestine (Fig. 8C). Although the Gfi1-positive progenitors were present, they failed to mature, suggesting that these cells undergo apoptosis, which is consistent with our observation of more apoptotic bodies in the crypts of the Mtgr1-null small intestines.
|
DISCUSSION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
It is intriguing that Gfi1-positive progenitor cells are maintained in the absence of Mtgr1 but that these cells fail to differentiate into mature goblet and Paneth cells. Gfi1 is a DNA binding transcriptional repressor that associates with MTG8/ETO (24). We have confirmed that, like MTG8/ETO, Mtgr1 also can associate with Gfi1 (unpublished data). Given that MTG8/ETO is only expressed in the gut during embryogenesis and Mtg16/Eto-2 is not expressed in the small intestine (data not shown), the loss of Mtgr1 may functionally inactivate Gfi1-mediated repression in the adult small intestine. If so, this would provide a molecular basis for the loss of Paneth and goblet cells that we observed in Mtgr1-null mice. However, Gfi-1-null mice also displayed increased numbers of endocrine cells (31) whereas Mtgr1-null small intestines have fewer endocrine cells (Fig. 5). Thus, loss of Mtgr1 could only be considered a partial phenocopy of Gfi-1 deletion in the gut.
In regard to a possible genetic interaction between Gfi1 and Mtgr1, it is also noteworthy that the Gfi1-null mice display neurological defects that include ataxia, walking with a head tilt, and progressive deafness due to inner ear defects (33). Consistent with loss of Mtgr1 genetically interacting with Gfi1, 10 to 15% of the Mtgr1-null mice with a mixed SvEv129 x C57BL/6 genetic background began to walk with a head tilt as they reached 6 to 8 months of age and these mice did not respond to noise (J. Amann, unpublished data). Given the gut and neurological similarities between the Gfi1- and Mtgr1-null mice and the previous association between Gfi1 and MTG8 (24), it is possible that impairment of Gfi1-mediated repression contributes to the phenotypes observed in Mtgr1-null mice.
Given the role that the MTG family plays in the formation of acute myeloid leukemia, we performed a preliminary analysis of hematopoiesis in Mtgr1-null mice but observed normal cellularity in the bone marrow. However, on a mixed SvEv129 x C57BL/6 genetic background we noted that a number of mice contained an enlarged thymus. Immunophenotyping with anti-CD3, anti-CD4, and anti-CD8, coupled with bromodeoxyuridine incorporation analysis, suggested that the expanded T-cell population was CD3 positive and cycling. However, this was the only consistent disruption of hematopoiesis observed (with antibodies to CD3, CD11, B220/CD45R, Ly6, and Ter119), and this phenotype was lost after three or four generations of breeding with C57BL/6 mice. The lack of a more dramatic hematopoietic phenotype in Mtgr1-null mice was likely due to compensation given that Mtg16/Eto-2 is widely expressed in hematopoietic cells and MTG8/ETO is also expressed, but perhaps in a more cell-type-restricted manner (5).
In addition to the loss of goblet and Paneth cells, we observed a loss of enteroendrocrine cells in the small intestines of Mtgr1-null mice, which cannot be explained by inactivation of Gfi1. Therefore, it is likely that the disruption of Mtgr1 affects repression mediated by multiple DNA binding factors that rely on MTG family members for repression. Hes1, Math1, and Tcf4 are required for lineage decision in the small intestine and thus are logical candidates, but only Hes1 is a repressor and inactivation of Hes1 affects the enterocytic lineage (Fig. 8A). Thus, if loss of Gfi1-mediated repression would explain the loss of goblet and Paneth cells, then one or more yet to be identified transcriptional repressors that recruit Mtgr1 are likely to mediate the loss of endocrine cells in Mtgr1-null mice. Moreover, this genetic analysis of Mtgr1 indicates that this factor is important for maintaining cell lineages in tissues that fail to express Mtg8 or Mtg16, which might imply a larger role for the MTG family of corepressors in other tissues (e.g., hematopoiesis) that may be uncovered when multiple MTG family members are removed.
|
ACKNOWLEDGMENTS |
|---|
This work was supported by National Institutes of Health grants RO1-CA87549, RO1-CA64140, RO1-CA77274, and RO1-CA112005 (S.W.H.); the Mouse Models of Human Cancer Consortium and CA46413 (R.J.C.); and Leukemia and Lymphoma Society postdoctoral fellowship 5074-03 (B.J.I.) and training grants T32DK07673 (A.M.) and T32-CA09582 (A.C.M.).
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
2. Batlle, E., J. T. Henderson, H. Beghtel, M. M. van den Born, E. Sancho, G. Huls, J. Meeldijk, J. Robertson, M. van de Wetering, T. Pawson, and H. Clevers. 2002. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111:251-263.[CrossRef][Medline]
3. Calabi, F., and V. Cilli. 1998. CBFA2T1, a gene rearranged in human leukemia, is a member of a multigene family. Genomics 52:332-341.[CrossRef][Medline]
4. Calabi, F., R. Pannell, and G. Pavloska. 2001. Gene targeting reveals a crucial role for MTG8 in the gut. Mol. Cell. Biol. 21:5658-5666.
5. Davis, J. N., L. McGhee, and S. Meyers. 2003. The ETO (MTG8) gene family. Gene 303:1-10.[CrossRef][Medline]
6. Davis, J. N., B. J. Williams, J. T. Herron, F. J. Galiano, and S. Meyers. 1999. ETO-2, a new member of the ETO-family of nuclear proteins. Oncogene 18:1375-1383.[CrossRef][Medline]
7. Erickson, P., J. Gao, K. S. Chang, T. Look, E. Whisenant, S. Raimondi, R. Lasher, J. Trujillo, J. Rowley, and H. Drabkin. 1992. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80:1825-1831.
8. Feinstein, P. G., K. Kornfeld, D. S. Hogness, and R. S. Mann. 1995. Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue. Genetics 140:573-586.[Abstract]
9. Fenrick, R., J. M. Amann, B. Lutterbach, L. Wang, J. J. Westendorf, J. R. Downing, and S. W. Hiebert. 1999. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol. Cell. Biol. 19:6566-6574.
10. Fracchiolla, N. S., G. Colombo, P. Finelli, A. T. Maiolo, and A. Neri. 1998. EHT, a new member of the MTG8/ETO gene family, maps on 20q11 region and is deleted in acute myeloid leukemias. Blood 92:3481-3484.
11. Frank, R., J. Zhang, H. Uchida, S. Meyers, S. W. Hiebert, and S. D. Nimer. 1995. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11:2667-2674.[Medline]
12. Gamou, T., E. Kitamura, F. Hosoda, K. Shimizu, K. Shinohara, Y. Hayashi, T. Nagase, Y. Yokoyama, and M. Ohki. 1998. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 91:4028-4037.
13. Gelmetti, V., J. Zhang, M. Fanelli, S. Minucci, P. G. Pelicci, and M. A. Lazar. 1998. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol. 18:7185-7191.
14. Hildebrand, D., J. Tiefenbach, T. Heinzel, M. Grez, and A. B. Maurer. 2001. Multiple regions of eto cooperate in transcriptional repression. J. Biol. Chem. 276:9889-9895.
15. Hope, K. J., L. Jin, and J. E. Dick. 2003. Human acute myeloid leukemia stem cells. Arch. Med. Res. 34:507-514.[CrossRef][Medline]
16. Jensen, J., E. E. Pedersen, P. Galante, J. Hald, R. S. Heller, M. Ishibashi, R. Kageyama, F. Guillemot, P. Serup, and O. D. Madsen. 2000. Control of endodermal endocrine development by Hes-1. Nat. Genet. 24:36-44.[CrossRef][Medline]
17. Kao, H. Y., M. Downes, P. Ordentlich, and R. M. Evans. 2000. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev. 14:55-66.
18. Kitabayashi, I., K. Ida, F. Morohoshi, A. Yokoyama, N. Mitsuhashi, K. Shimizu, N. Nomura, Y. Hayashi, and M. Ohki. 1998. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol. Cell. Biol. 18:846-858.
19. Korinek, V., N. Barker, P. Moerer, E. van Donselaar, G. Huls, P. J. Peters, and H. Clevers. 1998. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat. Genet. 19:379-383.[CrossRef][Medline]
20. Lenny, N., S. Meyers, and S. W. Hiebert. 1995. Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene 11:1761-1769.[Medline]
21. Linggi, B., C. Muller-Tidow, L. van de Locht, M. Hu, J. Nip, H. Serve, W. E. Berdel, B. van der Reijden, D. E. Quelle, J. D. Rowley, J. Cleveland, J. H. Jansen, P. P. Pandolfi, and S. W. Hiebert. 2002. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med. 8:743-750.[CrossRef][Medline]
22. Look, A. T. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
23. Lutterbach, B., J. J. Westendorf, B. Linggi, A. Patten, M. Moniwa, J. R. Davie, K. D. Huynh, V. J. Bardwell, R. M. Lavinsky, M. G. Rosenfeld, C. Glass, E. Seto, and S. W. Hiebert. 1998. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell. Biol. 18:7176-7184.
24. McGhee, L., J. Bryan, L. Elliott, H. L. Grimes, A. Kazanjian, J. N. Davis, and S. Meyers. 2003. Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism. J. Cell. Biochem. 89:1005-1018.[CrossRef][Medline]
25. Meyers, S., N. Lenny, and S. W. Hiebert. 1995. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol. Cell. Biol. 15:1974-1982.[Abstract]
26. Miyoshi, H., T. Kozu, K. Shimizu, K. Enomoto, N. Maseki, Y. Kaneko, N. Kamada, and M. Ohki. 1993. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12:2715-2721.[Medline]
27. Miyoshi, H., K. Shimizu, T. Kozu, N. Maseki, Y. Kaneko, and M. Ohki. 1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88:10431-10434.
28. Morohoshi, F., S. Mitani, N. Mitsuhashi, I. Kitabayashi, E. Takahashi, M. Suzuki, N. Munakata, and M. Ohki. 2000. Structure and expression pattern of a human MTG8/ETO family gene, MTGR1. Gene 241:287-295.[CrossRef][Medline]
29. Rowley, J. D. 1999. The role of chromosome translocations in leukemogenesis. Semin. Hematol. 36:59-72.[Medline]
30. Selsted, M. E., S. I. Miller, A. H. Henschen, and A. J. Ouellette. 1992. Enteric defensins: antibiotic peptide components of intestinal host defense. J. Cell Biol. 118:929-936.
31. Shroyer, N. F., D. W. Schultz, K. J. T. Venken, H. J. Bellen, and H. Y. Zoghbi. Genes Dev., in press.
32. Tybulewicz, V. L., C. E. Crawford, P. K. Jackson, R. T. Bronson, and R. C. Mulligan. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163.[CrossRef][Medline]
33. Wallis, D., M. Hamblen, Y. Zhou, K. J. Venken, A. Schumacher, H. L. Grimes, H. Y. Zoghbi, S. H. Orkin, and H. J. Bellen. 2003. The zinc finger transcription factor Gfi1, implicated in lymphomagenesis, is required for inner ear hair cell differentiation and survival. Development 130:221-232.
34. Wang, J., T. Hoshino, R. L. Redner, S. Kajigaya, and J. M. Liu. 1998. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. USA 95:10860-10865.
35. Yang, Q., N. A. Bermingham, M. J. Finegold, and H. Y. Zoghbi. 2001. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294:2155-2158.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|
